Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118


Quantitative Human Immunodeficiency Virus (HIV)-1 Antibodies Correlate With Plasma HIV-1 RNA and Cell-associated DNA Levels in Children on Antiretroviral Therapy.

McManus M, Henderson J, Gautam A, Brody R, Weiss ER, Persaud D, Mick E, Luzuriaga K; PACTG 356 Investigators .

Clin Infect Dis. 2018 Sep 5. doi: 10.1093/cid/ciy753. [Epub ahead of print]


No detection of CD4-independent human immunodeficiency virus 1 envelope glycoproteins in brain tissue of patients with or without neurological complications.

Quitadamo B, Peters PJ, Koch M, Luzuriaga K, Cheng-Mayer C, Clapham PR, Gonzalez-Perez MP.

Arch Virol. 2019 Feb;164(2):473-482. doi: 10.1007/s00705-018-4094-1. Epub 2018 Nov 10.


Genetic complexity in the replication-competent latent HIV reservoir increases with untreated infection duration in infected youth.

Brumme ZL, Sudderuddin H, Ziemniak C, Luzuriaga K, Jones BR, Joy JB, Cunningham CK, Greenough T, Persaud D.

AIDS. 2019 Feb 1;33(2):211-218. doi: 10.1097/QAD.0000000000002045.


Ultradeep single-molecule real-time sequencing of HIV envelope reveals complete compartmentalization of highly macrophage-tropic R5 proviral variants in brain and CXCR4-using variants in immune and peripheral tissues.

Brese RL, Gonzalez-Perez MP, Koch M, O'Connell O, Luzuriaga K, Somasundaran M, Clapham PR, Dollar JJ, Nolan DJ, Rose R, Lamers SL.

J Neurovirol. 2018 Aug;24(4):439-453. doi: 10.1007/s13365-018-0633-5. Epub 2018 Apr 23.


Severity of Acute Infectious Mononucleosis Correlates with Cross-Reactive Influenza CD8 T-Cell Receptor Repertoires.

Aslan N, Watkin LB, Gil A, Mishra R, Clark FG, Welsh RM, Ghersi D, Luzuriaga K, Selin LK.

MBio. 2017 Dec 5;8(6). pii: e01841-17. doi: 10.1128/mBio.01841-17.


HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.

Quitadamo B, Peters PJ, Repik A, O'Connell O, Mou Z, Koch M, Somasundaran M, Brody R, Luzuriaga K, Wallace A, Wang S, Lu S, McCauley S, Luban J, Duenas-Decamp M, Gonzalez-Perez MP, Clapham PR.

J Virol. 2018 Jan 2;92(2). pii: e00841-17. doi: 10.1128/JVI.00841-17. Print 2018 Jan 15.


Early Epstein-Barr Virus Genomic Diversity and Convergence toward the B95.8 Genome in Primary Infection.

Weiss ER, Lamers SL, Henderson JL, Melnikov A, Somasundaran M, Garber M, Selin L, Nusbaum C, Luzuriaga K.

J Virol. 2018 Jan 2;92(2). pii: e01466-17. doi: 10.1128/JVI.01466-17. Print 2018 Jan 15.


Identification of Emerging Macrophage-Tropic HIV-1 R5 Variants in Brain Tissue of AIDS Patients without Severe Neurological Complications.

Gonzalez-Perez MP, Peters PJ, O'Connell O, Silva N, Harbison C, Cummings Macri S, Kaliyaperumal S, Luzuriaga K, Clapham PR.

J Virol. 2017 Sep 27;91(20). pii: e00755-17. doi: 10.1128/JVI.00755-17. Print 2017 Oct 15.


Unique influenza A cross-reactive memory CD8 T-cell receptor repertoire has a potential to protect against EBV seroconversion.

Watkin LB, Mishra R, Gil A, Aslan N, Ghersi D, Luzuriaga K, Selin LK.

J Allergy Clin Immunol. 2017 Oct;140(4):1206-1210. doi: 10.1016/j.jaci.2017.05.037. Epub 2017 Jun 16. No abstract available.


Education and training of clinical and translational study investigators and research coordinators: A competency-based approach.

Calvin-Naylor NA, Jones CT, Wartak MM, Blackwell K, Davis JM, Divecha R, Ellerbeck EF, Kieburtz K, Koziel MJ, Luzuriaga K, Maddox J, Needler NA, Murphy S, Pemberton K, Radovich C, Rubinstein EP, Selker HP, Tenaerts P, Unsworth K, Wilson K, Wright JE, Barohn R, Shanley TP.

J Clin Transl Sci. 2017 Feb;1(1):16-25. doi: 10.1017/cts.2016.2. Epub 2017 Jan 13.


Paucity of Intact Non-Induced Provirus with Early, Long-Term Antiretroviral Therapy of Perinatal HIV Infection.

Rainwater-Lovett K, Ziemniak C, Watson D, Luzuriaga K, Siberry G, Petru A, Chen Y, Uprety P, McManus M, Ho YC, Lamers SL, Persaud D.

PLoS One. 2017 Feb 8;12(2):e0170548. doi: 10.1371/journal.pone.0170548. eCollection 2017.


High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.

Weiss ER, Alter G, Ogembo JG, Henderson JL, Tabak B, Bakiş Y, Somasundaran M, Garber M, Selin L, Luzuriaga K.

J Virol. 2016 Dec 16;91(1). pii: e01562-16. doi: 10.1128/JVI.01562-16. Print 2017 Jan 1.


Treatment interruption after early-treated perinatal HIV-1 infection.

Luzuriaga K, Persaud D.

AIDS. 2016 Sep 24;30(15):2381-3. doi: 10.1097/QAD.0000000000001226. No abstract available.


Eliminating Pediatric HIV-1 Infection.

Luzuriaga K, Mofenson LM.

N Engl J Med. 2016 Jul 14;375(2):193-4. doi: 10.1056/NEJMc1604016. No abstract available.


Early Combination Antiretroviral Therapy Limits Exposure to HIV-1 Replication and Cell-Associated HIV-1 DNA Levels in Infants.

McManus M, Mick E, Hudson R, Mofenson LM, Sullivan JL, Somasundaran M, Luzuriaga K; PACTG 356 Investigators.

PLoS One. 2016 Apr 22;11(4):e0154391. doi: 10.1371/journal.pone.0154391. eCollection 2016.


Challenges in the Elimination of Pediatric HIV-1 Infection.

Luzuriaga K, Mofenson LM.

N Engl J Med. 2016 Feb 25;374(8):761-70. doi: 10.1056/NEJMra1505256. Review. No abstract available.


The EPIICAL project: an emerging global collaboration to investigate immunotherapeutic strategies in HIV-infected children.

Palma P, Foster C, Rojo P, Zangari P, Yates A, Cotugno N, Klein N, Luzuriaga K, Pahwa S, Nastouli E, Gibb DM, Borkowsky W, Bernardi S, Calvez V, Manno E, Mora N, Compagnucci A, Wahren B, Muñoz-Fernández M, De Rossi A, Ananworanich J, Pillay D, Giaquinto C, Rossi P.

J Virus Erad. 2015;1(3):134-139. Epub 2015 Jun 30.


Early Combination Antiretroviral Therapy Limits HIV-1 Persistence in Children.

Luzuriaga K.

Annu Rev Med. 2016;67:201-13. doi: 10.1146/annurev-med-091114-111159. Review.


Recombination elevates the effective evolutionary rate and facilitates the establishment of HIV-1 infection in infants after mother-to-child transmission.

Sanborn KB, Somasundaran M, Luzuriaga K, Leitner T.

Retrovirology. 2015 Nov 16;12:96. doi: 10.1186/s12977-015-0222-0.


A Gene Expression Signature That Correlates with CD8+ T Cell Expansion in Acute EBV Infection.

Greenough TC, Straubhaar JR, Kamga L, Weiss ER, Brody RM, McManus MM, Lambrecht LK, Somasundaran M, Luzuriaga KF.

J Immunol. 2015 Nov 1;195(9):4185-97. doi: 10.4049/jimmunol.1401513. Epub 2015 Sep 28.


Cell-Associated HIV-1 DNA and RNA Decay Dynamics During Early Combination Antiretroviral Therapy in HIV-1-Infected Infants.

Uprety P, Chadwick EG, Rainwater-Lovett K, Ziemniak C, Luzuriaga K, Capparelli EV, Yenokyan G, Persaud D.

Clin Infect Dis. 2015 Dec 15;61(12):1862-70. doi: 10.1093/cid/civ688. Epub 2015 Aug 13.


Early antiretroviral therapy in children perinatally infected with HIV: a unique opportunity to implement immunotherapeutic approaches to prolong viral remission.

Klein N, Palma P, Luzuriaga K, Pahwa S, Nastouli E, Gibb DM, Rojo P, Borkowsky W, Bernardi S, Zangari P, Calvez V, Compagnucci A, Wahren B, Foster C, Munoz-Fernández MÁ, De Rossi A, Ananworanich J, Pillay D, Giaquinto C, Rossi P.

Lancet Infect Dis. 2015 Sep;15(9):1108-1114. doi: 10.1016/S1473-3099(15)00052-3. Epub 2015 Jul 14.


Reduced frequencies of polyfunctional CMV-specific T cell responses in infants with congenital CMV infection.

Gibson L, Barysauskas CM, McManus M, Dooley S, Lilleri D, Fisher D, Srivastava T, Diamond DJ, Luzuriaga K.

J Clin Immunol. 2015 Apr;35(3):289-301. doi: 10.1007/s10875-015-0139-3. Epub 2015 Feb 25.


Viremic relapse after HIV-1 remission in a perinatally infected child.

Luzuriaga K, Gay H, Ziemniak C, Sanborn KB, Somasundaran M, Rainwater-Lovett K, Mellors JW, Rosenbloom D, Persaud D.

N Engl J Med. 2015 Feb 19;372(8):786-8. doi: 10.1056/NEJMc1413931. No abstract available.


Very early combination antiretroviral therapy in infants: prospects for cure.

Rainwater-Lovett K, Luzuriaga K, Persaud D.

Curr Opin HIV AIDS. 2015 Jan;10(1):4-11. doi: 10.1097/COH.0000000000000127. Review.


Influence of age at virologic control on peripheral blood human immunodeficiency virus reservoir size and serostatus in perinatally infected adolescents.

Persaud D, Patel K, Karalius B, Rainwater-Lovett K, Ziemniak C, Ellis A, Chen YH, Richman D, Siberry GK, Van Dyke RB, Burchett S, Seage GR 3rd, Luzuriaga K; Pediatric HIV/AIDS Cohort Study.

JAMA Pediatr. 2014 Dec;168(12):1138-46. doi: 10.1001/jamapediatrics.2014.1560. Erratum in: JAMA Pediatr. 2015 Jan;169(1):96.


HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment.

Luzuriaga K, Tabak B, Garber M, Chen YH, Ziemniak C, McManus MM, Murray D, Strain MC, Richman DD, Chun TW, Cunningham CK, Persaud D.

J Infect Dis. 2014 Nov 15;210(10):1529-38. doi: 10.1093/infdis/jiu297. Epub 2014 May 21.


Absence of HIV-1 after treatment cessation in an infant.

Persaud D, Luzuriaga K.

N Engl J Med. 2014 Feb 13;370(7):678. doi: 10.1056/NEJMc1315498. No abstract available.


Epstein-Barr virus latent membrane protein 1 genetic variability in peripheral blood B cells and oropharyngeal fluids.

Renzette N, Somasundaran M, Brewster F, Coderre J, Weiss ER, McManus M, Greenough T, Tabak B, Garber M, Kowalik TF, Luzuriaga K.

J Virol. 2014 Apr;88(7):3744-55. doi: 10.1128/JVI.03378-13. Epub 2014 Jan 15.


Absence of detectable HIV-1 viremia after treatment cessation in an infant.

Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M Jr, Chun TW, Strain M, Richman D, Luzuriaga K.

N Engl J Med. 2013 Nov 7;369(19):1828-35. doi: 10.1056/NEJMoa1302976. Epub 2013 Oct 23.


Pilot study on the immunogenicity of paired Env immunogens from mother-to-child transmitted HIV-1 isolates.

Wang S, Kishko M, Wan S, Wang Y, Brewster F, Gray GE, Violari A, Sullivan JL, Somasundaran M, Luzuriaga K, Lu S.

Hum Vaccin Immunother. 2012 Nov 1;8(11):1638-47. doi: 10.4161/hv.22414. Epub 2012 Nov 1.


Persistence of Epstein-Barr virus in self-reactive memory B cells.

Tracy SI, Kakalacheva K, Lünemann JD, Luzuriaga K, Middeldorp J, Thorley-Lawson DA.

J Virol. 2012 Nov;86(22):12330-40. doi: 10.1128/JVI.01699-12. Epub 2012 Sep 5.


Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age.

Persaud D, Palumbo PE, Ziemniak C, Hughes MD, Alvero CG, Luzuriaga K, Yogev R, Capparelli EV, Chadwick EG.

AIDS. 2012 Jul 31;26(12):1483-90. doi: 10.1097/QAD.0b013e3283553638.


Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir.

Persaud D, Luzuriaga K, Ziemniak C, Muresan P, Greenough T, Fenton T, Blackford A, Ferguson K, Neu N, Cunningham CK.

AIDS. 2011 Nov 28;25(18):2227-34. doi: 10.1097/QAD.0b013e32834cdaba.


Genotypic and functional properties of early infant HIV-1 envelopes.

Kishko M, Somasundaran M, Brewster F, Sullivan JL, Clapham PR, Luzuriaga K.

Retrovirology. 2011 Aug 15;8:67. doi: 10.1186/1742-4690-8-67.


A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection.

Musich T, Peters PJ, Duenas-Decamp MJ, Gonzalez-Perez MP, Robinson J, Zolla-Pazner S, Ball JK, Luzuriaga K, Clapham PR.

J Virol. 2011 Mar;85(5):2397-405. doi: 10.1128/JVI.02187-10. Epub 2010 Dec 15.


Broad cross-reactive TCR repertoires recognizing dissimilar Epstein-Barr and influenza A virus epitopes.

Clute SC, Naumov YN, Watkin LB, Aslan N, Sullivan JL, Thorley-Lawson DA, Luzuriaga K, Welsh RM, Puzone R, Celada F, Selin LK.

J Immunol. 2010 Dec 1;185(11):6753-64. doi: 10.4049/jimmunol.1000812. Epub 2010 Nov 3.


Programmed Death-1 expression on Epstein Barr virus specific CD8+ T cells varies by stage of infection, epitope specificity, and T-cell receptor usage.

Greenough TC, Campellone SC, Brody R, Jain S, Sanchez-Merino V, Somasundaran M, Luzuriaga K.

PLoS One. 2010 Sep 23;5(9):e12926. doi: 10.1371/journal.pone.0012926.


Virologic and immunologic outcomes in HIV-infected Cambodian children after 18 months of highly active antiretroviral therapy (HAART).

Sophan S, Meng CY, Pean P, Harwell J, Hutton E, Trzmielina S, Somasundaran M, Luzuriaga K, Pugatch D.

Southeast Asian J Trop Med Public Health. 2010 Jan;41(1):126-37.


Infectious mononucleosis.

Luzuriaga K, Sullivan JL.

N Engl J Med. 2010 May 27;362(21):1993-2000. doi: 10.1056/NEJMcp1001116. Review. No abstract available. Erratum in: N Engl J Med. 2010 Oct 7;363(15):1486.


Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination.

Mehta N, Cunningham CK, Flynn P, Pepe J, Obaro S, Kapogiannis BG, Bethel J, Luzuriaga K; Adolescent Trials Network for HIV/AIDS Interventions.

Vaccine. 2010 May 7;28(21):3672-8. doi: 10.1016/j.vaccine.2010.03.022. Epub 2010 Mar 28.


Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy.

Shiu C, Cunningham CK, Greenough T, Muresan P, Sanchez-Merino V, Carey V, Jackson JB, Ziemniak C, Fox L, Belzer M, Ray SC, Luzuriaga K, Persaud D; Pediatric AIDS Clinical Trials Group P1059 Team.

J Virol. 2009 Oct;83(19):9731-42. doi: 10.1128/JVI.00570-09. Epub 2009 Jul 15.


Low-cost HIV-1 diagnosis and quantification in dried blood spots by real time PCR.

Mehta N, Trzmielina S, Nonyane BA, Eliot MN, Lin R, Foulkes AS, McNeal K, Ammann A, Eulalievyolo V, Sullivan JL, Luzuriaga K, Somasundaran M.

PLoS One. 2009 Jun 5;4(6):e5819. doi: 10.1371/journal.pone.0005819.


Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy.

Chadwick EG, Pinto J, Yogev R, Alvero CG, Hughes MD, Palumbo P, Robbins B, Hazra R, Serchuck L, Heckman BE, Purdue L, Browning R, Luzuriaga K, Rodman J, Capparelli E; International Maternal Pediatric Adolescent Clinical Trials Group (IMPAACT) P1030 Team.

Pediatr Infect Dis J. 2009 Mar;28(3):215-9. doi: 10.1097/INF.0b013e31818cc053.


Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy.

Greenough TC, Cunningham CK, Muresan P, McManus M, Persaud D, Fenton T, Barker P, Gaur A, Panicali D, Sullivan JL, Luzuriaga K; Pediatric AIDS Clinical Trials Group P1059 Team.

Vaccine. 2008 Dec 9;26(52):6883-93. doi: 10.1016/j.vaccine.2008.09.084. Epub 2008 Oct 20.


Diminished human immunodeficiency virus type 1 DNA yield from dried blood spots after storage in a humid incubator at 37 degrees C compared to -20 degrees C.

Mitchell C, Jennings C, Brambilla D, Aldrovandi G, Amedee AM, Beck I, Bremer JW, Coombs R, Decker D, Fiscus S, Fitzgibbon J, Luzuriaga K, Moye J, Palumbo P, Reichelderfer P, Somasundaran M, Stevens W, Frenkel L; Dried Blood Spot Working Group of the Infant Maternal Pediatric Adolescent AIDS Clinical Trials Network.

J Clin Microbiol. 2008 Sep;46(9):2945-9. doi: 10.1128/JCM.00359-08. Epub 2008 Jul 9.


Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors.

Peters PJ, Duenas-Decamp MJ, Sullivan WM, Brown R, Ankghuambom C, Luzuriaga K, Robinson J, Burton DR, Bell J, Simmonds P, Ball J, Clapham PR.

Retrovirology. 2008 Jan 18;5:5. doi: 10.1186/1742-4690-5-5.


Identification and characterization of HIV-1 CD8+ T cell escape variants with impaired fitness.

Sanchez-Merino V, Farrow MA, Brewster F, Somasundaran M, Luzuriaga K.

J Infect Dis. 2008 Jan 15;197(2):300-8. doi: 10.1086/524845.


Lack of alternative coreceptor use by pediatric HIV-1 R5 isolates for infection of primary cord or adult peripheral blood mononuclear cells.

Sullivan WM, Dorr P, Perros M, Hudson R, Leif J, Luzuriaga K, Clapham PR.

Arch Virol. 2008;153(2):363-6. Epub 2007 Dec 13.


Mother-to-child transmission of HIV: a global perspective.

Luzuriaga K.

Curr Infect Dis Rep. 2007 Nov;9(6):511-7.


Supplemental Content

Loading ...
Support Center